Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GTPase activating protein and VPS9 domains 1 (GAPVD1) is a cytosolic protein that functions as both a GTPase-activating protein (GAP) and a guanine nucleotide exchange factor (GEF)[1][3][9]. It activates Rab5 and Rab31, small GTPases involved in endocytosis and vesicle trafficking, and also exhibits GAP activity toward Ras[1][3]. GAPVD1 is essential for Rab5A activation during apoptotic cell engulfment and plays a role in EGFR trafficking and degradation[1][3]. It participates in insulin-stimulated plasma membrane phosphatidylinositol-3-phosphate formation, regulates LC2A4/GLUT4 trafficking, and is involved in endocytic transport[1][3][9]. Its dysfunction has been associated with hereditary steroid-resistant nephrotic syndrome and coenzyme Q10 deficiency[3]. No drugs or specific safety concerns are documented as of the latest available data.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on GTPase activating protein and VPS9 domains 1 (GAPVD1).